economy

A research group of the Medical Biology Institute under the Academy of Medical Sciences developed an injection for the treatment of psoriasis, one of tough problems in clinical practice.

According to section chief Hong Ju Hyok, whereas the morbidity of intractable chronic infectious, allergic, autoimmune and cancerous diseases is on the increase worldwide, the response to treatment with various corresponding chemicals is on the decrease, leading to a higher recurrence rate, and therefore many countries are switching to treatment with more advanced and effective biologicals.

However, neither preparation methods nor efficacy were published at the time of research.

The research group undertaking the unfamiliar task intensified research and finally developed a medicine for treating psoriasis with remarkable effects and little adverse effect, which can reach world standards.

By using bioengineering technology, they established the rational methods of refining active components and blending them, and set out in detail the features of the action of the medicine and its application method.

The B-modulin injection they developed is said to have significant part in suppressing the response to various stresses, infections, chronic diseases, environmental changes, trauma and other factors causing and exacerbating psoriasis, in reducing the recurrence rate of the disease and in retarding the recurrence of it.

Clinical practice has proved that the injection is highly effective in the treatment of allergic, chronic infectious and other diseases and can shorten the treatment period and reduce the recurrence rate.